A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer-Reference-Cited by-同舟云学术

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer

Published:2022-09-20 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Alam Mohammad R,Singh Shashi B,Thapaliya Shreeya,Shrestha Shreeya,Deo Sulav,Khanal Kishor

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference64 articles.

1. Key statistics for prostate cancer. Accessed. (2022). Accessed. August 19, 2022: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html..

2. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer;Halabi S;J Clin Oncol,2008

3. Prostate-specific membrane antigen ligands for imaging and therapy;Eiber M;J Nucl Med,2017

4. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions;Afshar-Oromieh A;J Nucl Med,2015

5. An overview of targeted alpha therapy;Kim YS;Tumour Biol,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreased levels of PTCSC3 promote the deterioration of prostate cancer and affect the prognostic outcome of patients through sponge miR-182-5p;BMC Urology;2024-07-12

2. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2;Molecules;2024-06-28

3. A High-Resolution Portable Gamma-Camera for Estimation of Absorbed Dose in Molecular Radiotherapy;IEEE Transactions on Radiation and Plasma Medical Sciences;2024-05

4. Total chemical synthesis of PSMA-617: an API for prostate cancer endotherapeutic applications;Radiochimica Acta;2024-02-14

5. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens;Diagnostics;2024-01-14